Amneal Pharmaceuticals Revenue and Competitors

Bridgewater, NJ USA

Location

$854M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Amneal Pharmaceuticals's estimated annual revenue is currently $2.1B per year.(i)
  • Amneal Pharmaceuticals's estimated revenue per employee is $386,194
  • Amneal Pharmaceuticals's total funding is $854M.

Employee Data

  • Amneal Pharmaceuticals has 5360 Employees.(i)
  • Amneal Pharmaceuticals grew their employee count by 8% last year.

Amneal Pharmaceuticals's People

NameTitleEmail/Phone
1
Executive Assistant To Co-CEOReveal Email/Phone
2
VP, Global Regulatory AffairsReveal Email/Phone
3
VP, R&DReveal Email/Phone
4
VP Transdermal Product DevelopmentReveal Email/Phone
5
SVP, US QualityReveal Email/Phone
6
SVP & CFOReveal Email/Phone
7
SVP, General CounselReveal Email/Phone
8
VP Supply ChainReveal Email/Phone
9
VP, Specialty Sales & MarketingReveal Email/Phone
10
VP, Market Access and TradeReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is Amneal Pharmaceuticals?

Privately owned and operated since 2001, Amneal is a growth-oriented company dedicated to developing and manufacturing the finest quality generic prescription drugs. We welcome you to tour our site and discover the many facets of our company.

keywords:N/A

$854M

Total Funding

5360

Number of Employees

$2.1B

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Amneal Pharmaceuticals News

2022-04-20 - Amneal secures second US biosimilars approval

Last week saw the US Food and Drug Administration (FDA) approve the Biologics License Application (BLA) from Amneal Pharmaceuticals Inc for...

2022-04-17 - FDA Approves Alymsys® (bevacizumab-maly), a Biosimilar of ...

"The entire Brand Institute and Drug Safety Institute Team congratulates Amneal Pharmaceuticals and mAbxience on the FDA approval of ALYMSYS,"...

2022-03-30 - Almirall, LLC v. Amneal Pharmaceuticals LLC (Fed. Cir. 2022 ...

Amneal Pharmaceuticals LLC. The case arose in an inter partes review (IPR) proceeding by challenger Amneal over Almirall's U.S. Patent No.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1313.3M653413%N/A
#2
$2166.6M86325%N/A
#3
$2600.4M103606%N/A
#4
$38500M1036752%N/A